MedTrace Logo

Biomarkers for Differentiating Reversible and Irreversible Pulpitis

NCT07658742 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-07-31

No results posted yet for this study

Summary

This observational study aims to evaluate the role of inflammatory, oxidative stress, neurogenic, and immunological biomarkers obtained from pulpal blood in the differential diagnosis of normal pulp, reversible pulpitis, and irreversible pulpitis.

A total of 75 teeth from systemically healthy individuals aged 12-35 years will be included and classified into three groups: normal pulp, reversible pulpitis, and irreversible pulpitis, based on clinical examination, radiographic findings, and pulp sensibility tests. No additional treatment procedures will be performed for research purposes. All dental procedures will be carried out according to routine clinical protocols.

During routine treatment, after pulp exposure, approximately 50 μL of pulpal blood that would otherwise be discarded as medical waste will be collected using a micropipette. Samples will be stored and analyzed using Enzyme-Linked ImmunoSorbent Assay (ELISA) to determine the levels of inflammatory, neurogenic, immunological, and oxidative stress biomarkers. The results will be compared among the three groups to identify biomarkers that may improve the accuracy of pulpitis diagnosis and support clinical decision-making.

Conditions

  • Reversible Pulpitis
  • Irreversible Pulpitis
  • Healthy Pulp

Interventions

DIAGNOSTIC_TEST

Pulpal Blood Biomarker Analysis

Collection of pulpal blood samples during routine dental treatment followed by biomarker analysis using ELISA.

Sponsors & Collaborators

  • Safa

    lead OTHER

Eligibility

Min Age
12 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-06-01
Completion
2026-06-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07658742 on ClinicalTrials.gov